Immunotherapy Archives

pdcLine Pharma dendritic cell cancer vaccine

News and Trends 22 Jan 2020

Off-The-Shelf Lung Cancer Vaccine Clinical Trial Gets €20M Boost

The French-Belgian company PDC*Line Pharma has raised a €20M Series B round to fund an ongoing phase I/II trial of its off-the-shelf therapeutic vaccine for lung cancer. The total €20M consists of €13.9M in equity investments and €6.1M in loans and subsidies from the Walloon Region of Belgium. PDC*Line’s current investors took part in the […]

January 22, 2020 - 2 minutesmins - By Jonathan Smith

News and Trends 16 Jan 2020

BioNTech Expands Cancer Portfolio With US Biotech Acquisition

German cancer specialist BioNTech will acquire US T-cell therapy biotech Neon Therapeutics in a deal worth €60M, both to expand its cancer therapy pipeline and establish a US base. The deal is expected to complete in the second half of 2020, after which Neon will operate as a subsidiary of BioNTech. BioNTech has arguably scooped […]

January 16, 2020 - 2 minutesmins - By Helen Albert

tumor cancer immunotherapy alderaan biotech

News and Trends 9 Jan 2020

French Biotech Raises €19M to Hit Phase I with Cancer Immunotherapy

Alderaan Biotechnology has raised an €18.5M Series A round to push its lead cancer immunotherapy drug to phase I. The UK VC firm Medicxi and the returning French VC investor Advent France Biotechnology contributed to the round. Alderaan, whose name was inspired by a fictional planet in the Star Wars movies, will use part of […]

January 9, 2020 - 2 minutesmins - By Jonathan Smith

News and Trends 13 Dec 2019

Transgene’s Cancer Vaccine Abandoned after Phase II Fail

French biotech Transgene has ceased the development of a therapeutic cancer vaccine that failed to shrink tumors in patients with lung cancer in a phase II trial. In the phase II trial, Transgene tested its therapeutic cancer vaccine in combination with chemotherapy and the checkpoint inhibitor drug nivolumab, marketed as Opdivo. The treatment failed to […]

December 13, 2019 - 2 minutesmins - By Jonathan Smith

cancer immunotherapy immunos therapeutics

News and Trends 11 Dec 2019

€14M Series A to Fund Cancer Immunotherapy Boosting Checkpoint Inhibitors

The Swiss biotech ImmunOs Therapeutics has raised a Series A round of €13.7M (CHF 15M) that will fund the first human trials of its cancer immunotherapy that could improve the response of cancer patients to checkpoint inhibitors. The round was co-led by the Swiss life sciences venture capital firm BioMedPartners and by Pfizer Ventures. The […]

December 11, 2019 - 2 minutesmins - By Jonathan Smith

Interview 11 Dec 2019

Collaboration Between Founders and Investors Primes Biotech Startups for Success

How can entrepreneurs work with investors to maximize the chances of their company succeeding? Venture capital partner Nanna Lüneborg and biotech entrepreneur Mai-Britt Zocca spoke at Labiotech Refresh in Copenhagen about their experiences in founding IO Biotech, a Danish biotech startup that develops cancer immunotherapies. Zocca and Lüneborg were both involved in setting up IO […]

December 11, 2019 - 5 minutesmins - By Jonathan Smith

colorectal cancer mologen cancer immunotherapy

News and Trends 6 Dec 2019

Update: Cancer Immunotherapy Biotech Files for Insolvency

Update (06/12/2019): Following the phase III failure of its immunotherapy drug for colorectal cancer in the summer, the German company Mologen has filed for insolvency. Published 06/08/2019 A DNA immunotherapy drug developed by the German company Mologen has failed to improve the survival of patients with colorectal cancer in a phase III trial. The phase […]

December 6, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 4 Dec 2019

€48M Series B Fuels Immunotherapies for Cancer and Autoimmune Diseases

ImCheck Therapeutics has raised a Series B round worth €48M to fund the development of first-in-class immunotherapies that treat cancer and autoimmune diseases by targeting a rare type of immune cells called a gamma delta T-cell. ImCheck Therapeutics’ Series B round was led by Pfizer Ventures — the venture capital arm of the big pharma […]

December 4, 2019 - 3 minutesmins - By Jonathan Smith

cancer immunotherapy gammadelta therapeutics adaptate biotherapeutics

News and Trends 16 Oct 2019

GammaDelta Therapeutics Spins Out Cancer Immunotherapy Biotech

The UK biotech GammaDelta Therapeutics has founded Adaptate Biotherapeutics to develop cancer immunotherapies based on antibodies that boost a rare type of immune cell. Adaptate Biotherapeutics is a spin-out of GammaDelta Therapeutics, a London company founded in 2016 that specializes in using a rare type of immune cells, known as gamma delta T-cells, to fight […]

October 16, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 15 Oct 2019

German Cancer Virotherapy Biotech Launches with €12M Series A

Abalos Therapeutics launches today with €12M in Series A funding to get the development of its arenavirus-based cancer therapies off the ground. Boehringer Ingelheim Venture Fund and Gründerfonds Ruhr co-led the investment round, with additional contributions from NRW.BANK and High-Tech Gründerfonds. Abalos, which is based in Essen, Germany, will focus on developing anti-cancer drugs with […]

October 15, 2019 - 2 minutesmins - By Helen Albert

cancer treatments personalized technology

In Depth 15 Oct 2019

Four New Technologies That Will Change Cancer Treatment

New approaches to tame the immune system in the fight against cancer are getting us closer to a future where cancer becomes a curable disease. Personalized vaccines, cell therapy, gene editing and microbiome treatments are four technologies that will change the way cancer is treated. Curing cancer is certainly one of the big challenges of […]

October 15, 2019 - 9 minutesmins - By Clara Rodríguez Fernández

More News! 7 Oct 2019

UK Biotech Launches with €30M Series A to Treat Autoimmune Disease

MiroBio has spun out of the University of Oxford with a Series A round of €30M (£27M) to develop treatments for autoimmune diseases that don’t disrupt the immune system as a whole. The big Series A round accompanying MiroBio’s launch was co-led by the university’s investor partner Oxford Sciences Innovation and the US investor Samsara […]

October 7, 2019 - 2 minutesmins - By Jonathan Smith

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Immunotherapy

Off-The-Shelf Lung Cancer Vaccine Clinical Trial Gets €20M Boost

BioNTech Expands Cancer Portfolio With US Biotech Acquisition

French Biotech Raises €19M to Hit Phase I with Cancer Immunotherapy

Transgene’s Cancer Vaccine Abandoned after Phase II Fail

€14M Series A to Fund Cancer Immunotherapy Boosting Checkpoint Inhibitors

Collaboration Between Founders and Investors Primes Biotech Startups for Success

Update: Cancer Immunotherapy Biotech Files for Insolvency

€48M Series B Fuels Immunotherapies for Cancer and Autoimmune Diseases

GammaDelta Therapeutics Spins Out Cancer Immunotherapy Biotech

German Cancer Virotherapy Biotech Launches with €12M Series A

Four New Technologies That Will Change Cancer Treatment

UK Biotech Launches with €30M Series A to Treat Autoimmune Disease

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!